JAK Janus Kinase
| Zeile 14: | Zeile 14: | ||
{{tp|p=32032529|t=2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease |pdf=|usr=}} | {{tp|p=32032529|t=2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease |pdf=|usr=}} | ||
| + | {{tp|p=32251638|t=2020. Baricitinib for COVID-19: a suitable treatment?|pdf=|usr=}} | ||
| + | {{tp|p=32251639|t=2020. Baricitinib for COVID-19: a suitable treatment? - Authors reply |pdf=|usr=}} | ||
'''Fedratinib''' | '''Fedratinib''' | ||
{{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}} | {{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}} | ||
Version vom 18. Juni 2020, 13:13 Uhr
32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19
Tofacitinib
32342098 ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib
Baricitinib
32259575 ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
32333918 ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
32032529 2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
32251638 2020. Baricitinib for COVID-19: a suitable treatment?
32251639 2020. Baricitinib for COVID-19: a suitable treatment? - Authors reply
Fedratinib
| 32205092 ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |
